Astra shakes things up with Covid-19 pricing disclosure
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.
How Labour’s UK generic drugs plan could have been better
Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.
Pricing questions remain as Novo gets the nod for oral sema
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
Bayer could become the latest casualty of Roche’s targeted pricing
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
Pfizer shoots for a high price with tafamidis
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
Peanut therapy makers face pricing pushback
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…
Rebate ban would not necessarily equal savings, Icer says
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
Lilly takes a leaf out of Mylan’s book to defuse insulin price complaints
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Big pharma execs decry rebates, but how big might list price cuts be?
Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
